Top Page
InhaleRx Limited
(Sydney:IRX)
InhaleRx Limited (IRX) vs. iShares MSCI Australia ETF (EWA)
InhaleRx Limited Business Overview & Revenue Model
InhaleRx Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 770.82K | 335.10K | 1.20M | 24.80K | 167.30K | 12.56K |
| Gross Profit | 770.82K | 335.10K | 1.20M | 24.80K | 52.07K | -26.43K |
| EBITDA | 0.00 | 0.00 | -1.41M | -1.94M | -1.11M | -1.21M |
| Net Income | -1.39M | -1.28M | -1.44M | -1.93M | -1.11M | -1.21M |
Balance Sheet | ||||||
| Total Assets | 1.44M | 712.40K | 1.58M | 2.26M | 2.93M | 1.90M |
| Cash, Cash Equivalents and Short-Term Investments | 481.32K | 194.91K | 715.82K | 2.13M | 2.80M | 1.72M |
| Total Debt | 336.25K | 34.06K | 560.27K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.31M | 776.37K | 911.41K | 355.32K | 253.34K | 580.10K |
| Stockholders Equity | -877.11K | -63.97K | 665.47K | 1.93M | 2.68M | 1.32M |
Cash Flow | ||||||
| Free Cash Flow | -293.46K | -368.77K | -1.96M | -1.85M | -1.19M | -1.09M |
| Operating Cash Flow | -293.46K | -368.77K | -1.96M | -1.85M | -1.16M | -1.09M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -175.00 | -25.09K | -4.30K |
| Financing Cash Flow | 442.15K | -152.14K | 544.29K | 1.18M | 2.26M | 2.41M |
InhaleRx Limited Technical Analysis
InhaleRx Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.72M | -2.58 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$34.03M | -5.45 | -58.27% | ― | -7.20% | 28.70% | |
43 Neutral | AU$49.00M | -8.46 | -513.22% | ― | -34.06% | 75.47% | |
42 Neutral | AU$5.42M | -3.55 | ― | ― | ― | -55.00% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
37 Underperform | AU$12.36M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
InhaleRx Limited Corporate Events
InhaleRx Limited has secured strong shareholder backing at its 29 January general meeting, with all eight resolutions passed by poll, including the ratification of prior share issues, approvals for additional placement securities and options under an existing funding facility, and a change of the company’s name to Nexalis Therapeutics Limited. The broad support for these capital and governance measures reinforces the company’s funding base and strategic flexibility as it accelerates development of its inhaled and oral therapies for pain and mental health, positioning the renamed Nexalis Therapeutics to pursue U.S. regulatory pathways and address significant treatment gaps in these high-need markets.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
InhaleRx Limited has scheduled a general meeting for shareholders to be held online at 4:00pm AEDT on Thursday, 29 January 2026. The meeting will cover eight resolutions to be decided by poll, with procedures outlined for virtual attendees to raise IT issues and submit questions, underscoring the company’s continued use of digital channels for shareholder engagement and formal decision-making.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
InhaleRx reported progress across its clinical portfolio for the quarter ended 31 December 2025, underpinned by fresh funding and preparation for key trials. The company raised $857,730 through a placement and entitlement offer to support operating costs and extended its funding agreement with Linlithgow Family Office by $12.6 million to advance SRX-25 to Phase 3 readiness, strengthening its financial position for near- and mid-term development. Operationally, InhaleRx completed manufacturing of trial drugs for the Phase 2 trial of IRX-211 for breakthrough cancer pain and the Phase 1 trial of IRX-616a for panic disorder, executed clinical trial agreements with key Australian sites, and advanced protocol and documentation for the SRX-25 program. While the start of patient screening for the IRX-211 Phase 2 trial was delayed by site budget negotiations, these issues have now been resolved as the company prepares for first patient dosing, positioning its lead asset in a large and underserved cancer pain market where there are no FDA-approved non-opioid inhaled treatments and fentanyl-based rapid-onset options have recently been withdrawn in the US.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
InhaleRx Limited reported its quarterly cash flow for the period ended 31 December 2025, showing net operating cash outflows of A$628,000 for the quarter and A$899,000 year-to-date, largely driven by research and development and administrative expenses, partly offset by government grants and tax incentives. The company recorded no investing cash flows during the period, but strengthened its cash position through A$535,000 in equity issuance and A$774,000 in new borrowings (partly offset by repayments and transaction costs), resulting in net financing inflows of A$894,000 and an overall increase in cash and cash equivalents of A$170,000 for the quarter, indicating continued reliance on external funding to support its operations.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
InhaleRx Limited has completed the first tranche of its equity placement, receiving a final $172,500 and issuing 6.9 million ordinary shares at $0.025 each, bringing total funds raised under Tranche 1 to $600,000 before costs as part of a broader $750,000 placement managed by Peak Asset Management and placed with professional and sophisticated investors. Investors in the placement are entitled to one free attaching option for every two shares, exercisable at $0.042 for two years, while additional options to Peak and a $35,000 participation by director Ron Wise remain subject to shareholder approval at a general meeting on 29 January 2026, underscoring ongoing capital-raising efforts to support the company’s clinical development programs and strengthen its position in the specialised inhaled-therapies market.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
InhaleRx Limited has called an online-only general meeting of shareholders for 4:00pm AEDT on 29 January 2026, with investors able to watch, ask questions and vote via a virtual platform. The company is urging shareholders to pre-register for the webcast, submit proxy votes by 27 January 2026, and access the notice of meeting and explanatory materials electronically via its share registry or the ASX, reflecting a continued shift to digital governance and engagement practices.
InhaleRx Limited has issued a proxy voting form and instructions for shareholders ahead of its general meeting scheduled for 4:00pm (AEDT) on Thursday, 29 January 2026, to be held virtually. The materials outline how shareholders can appoint proxies, submit voting instructions through various channels, and direct votes on a series of resolutions, including ratification of prior share issues, approvals for multiple tranches of placement securities and options (including to the lead manager and under a facility agreement), and a proposal to change the company’s name to Nexalis Therapeutics Limited. The documentation clarifies procedural rules for proxy appointments, default voting by the chair, and corporate representation, underscoring a significant capital-structure and branding agenda that, if approved, would formalise recent financing activities and rebrand the company, potentially signalling a strategic repositioning for investors and other stakeholders.
InhaleRx Limited has called a virtual general meeting of shareholders for 29 January 2026 to consider a series of capital-raising related resolutions. The agenda includes ratification of prior share issues and Tranche 1 placement shares, approval to issue additional Tranche 1 and Tranche 2 placement shares and options (including securities to Dr Ron Wise), and approval for issuing options to lead manager Peak Asset Management, steps that collectively confirm and expand the company’s recent equity placements and associated incentives, with implications for capital structure and potential dilution for existing shareholders.
InhaleRx Limited has disclosed a change in the indirect interests of director Dr Ronald Wise following his participation in the company’s recent entitlement offer. Through beneficiary interests in Sassey Pty Ltd entities, Dr Wise acquired 113,317 fully paid ordinary shares at an issue price of $0.025 per share and 56,659 free attaching unlisted options exercisable at $0.042 expiring on 23 December 2027, increasing his holdings to 2,606,302 shares, 746,736 performance rights, 500,000 unlisted options at $0.12 expiring 7 July 2028, and 56,659 new options. The transaction, which involved no disposals and did not occur during a closed trading period, signals director support for the capital raising and modestly strengthens insider alignment with shareholders.
InhaleRx Limited has disclosed a change in the indirect holdings of director Sean Williams following his participation in the company’s recent entitlement offer. Williams holds his interests through TG Advisory Pty Ltd as trustee for the Williams Glenair Family Account and the S & C Williams Super Account, reflecting a mix of fully paid ordinary shares, unlisted options and performance rights.
The disclosure shows Williams acquired 42,777 new shares at an issue price of $0.025 under the entitlement offer, increasing his total shareholding to 983,920 shares, and received 21,389 free attaching options expiring in December 2027, with all existing option and performance right holdings unchanged. The move modestly lifts director equity exposure and underscores board support for the capital-raising initiative, which may be viewed positively by investors monitoring alignment between management and shareholder interests.
InhaleRx has closed its pro-rata non-renounceable entitlement offer, raising $107,730 before costs from applications for 4.3 million new shares and associated options, below the maximum possible amount and leaving a shortfall of approximately $139,938 that the company is now working with lead manager Peak Asset Management to place on the same terms within three months. Together with a two-tranche placement of 30 million new shares and 15 million options expected to raise $750,000 before costs—of which $427,500 has already been received and the balance is committed subject to shareholder approval—the company has secured total funds received or committed of $857,730 to support its ongoing capital needs and development programs, modestly strengthening its balance sheet as it advances its inhaled drug candidates in pain and mental health indications.
InhaleRx Limited has notified the market of a new issue of unquoted equity securities, consisting of 2,154,603 deferred options (IRXAK) expiring on 22 December 2027. The options, which were previously flagged to the market, are not quoted and are not intended to be quoted on the ASX, indicating a capital management step that may be tied to incentive structures or specific financing arrangements rather than broad public issuance.
InhaleRx Limited has applied to the ASX for quotation of 4,309,185 new fully paid ordinary shares under its IRX ticker. The issuance of these securities, previously flagged in an Appendix 3B, will expand the company’s quoted share base and may enhance its trading liquidity and capital position ahead of future operational or strategic initiatives.
InhaleRx Limited has issued 17,100,000 ordinary shares without disclosure to investors, in compliance with the Corporations Act. This move is part of their strategy to accelerate the development of their inhaled therapies, which could significantly impact the market by addressing critical gaps in treatment options for conditions like cancer pain and mental health disorders.
InhaleRx Limited has released a presentation providing summary information about its current activities, emphasizing its focus on innovative therapies for pain management and mental health. The presentation serves informational purposes and cautions against relying on forward-looking statements, highlighting the inherent risks and uncertainties that could impact the company’s future performance.
InhaleRx Limited has announced the quotation of 17,100,000 fully paid ordinary securities on the ASX, as part of a previously disclosed transaction. This move is expected to enhance the company’s financial flexibility and potentially strengthen its market position by increasing its capital base, thereby benefiting stakeholders through improved operational capabilities.
InhaleRx Limited has issued 17,100,000 ordinary shares at $0.025 each, raising $427,500 as part of a larger capital raise effort of up to $1,000,000. The placement, managed by Peak Asset Management, involves professional and sophisticated investors and includes options for additional shares subject to shareholder approval. This capital raise is expected to support the company’s strategic initiatives in drug development and enhance its market positioning.
InhaleRx Limited has announced a non-renounceable pro-rata entitlement offer to raise approximately $250,000, offering 1 new share for every 22 shares held at 2.5 cents per share, along with free attaching options. The offer is restricted to shareholders in Australia and New Zealand, excluding those with registered addresses elsewhere due to cost and regulatory considerations. This move is part of the company’s strategy to secure funding for its drug development projects, potentially impacting its market positioning by addressing critical gaps in current treatment options.
InhaleRx Limited has announced the dispatch of its Entitlement Offer Prospectus, opening the offer for subscription to eligible shareholders. The offer is part of the company’s strategy to fund the development of its inhaled therapies, with significant economic opportunities anticipated for shareholders. The timeline for the offer includes a closing date on December 17, 2025, and subsequent announcements and meetings scheduled into January 2026.
InhaleRx Limited has secured an additional $12.6 million in funding from the Linlithgow Family Office to advance the development of its SRX-25 drug, a new oral therapy targeting treatment-resistant depression. This funding will support manufacturing, non-clinical work, and Phase 1/2 trials, positioning the company to move SRX-25, along with IRX-211 and IRX-616a, into Phase III trials. The funding arrangement includes a structured loan facility and options for shares, aligning with the company’s strategic goals to enhance its market position and ensure the value of its medications is reflected in its share price.
InhaleRx Limited has announced a proposed issue of 6,000,000 unlisted options with an exercise price of $0.042, set to expire on December 22, 2027. This strategic move is intended to strengthen the company’s financial position and support its ongoing operations, potentially enhancing its market presence and offering growth opportunities for stakeholders.
InhaleRx Limited announced a proposed issue of securities, including 15 million unlisted options and 30 million ordinary fully paid shares, set to be issued on November 28, 2025. This strategic move is expected to bolster the company’s financial position, potentially enhancing its market presence and providing additional capital for future growth initiatives.
InhaleRx Limited has announced a proposed issuance of securities, including 4,953,367 unlisted options and 9,906,734 ordinary fully paid shares. This move, set to take place in December 2025, is part of a standard pro rata issue, which is non-renounceable. The issuance aims to bolster the company’s financial standing and potentially enhance its market position by increasing its capital base. This strategic financial maneuver could have significant implications for stakeholders, as it may influence the company’s operational capabilities and competitive edge in the pharmaceutical industry.
InhaleRx Limited has announced a non-renounceable entitlement offer to its eligible shareholders, allowing them to purchase up to 9,906,734 new shares at a price of $0.025 per share. This offer, scheduled to open on December 5, 2025, and close on December 17, 2025, includes one free attaching new option for every two new shares subscribed, which could potentially impact the company’s market positioning by increasing its capital base.
InhaleRx Limited has announced the addition of SRX-25, a ketamine-based oral fixed-dose drug, to its development pipeline, targeting treatment-resistant depression (TRD). This new formulation aims to improve patient access and adherence by offering a more convenient oral administration compared to existing intranasal options. The development will utilize the 505(b)(2) regulatory pathway to expedite progress and reduce costs, with funding support from the Linlithgow Family Office. The global TRD market is expected to grow significantly, and SRX-25 could enhance InhaleRx’s market position by addressing current treatment limitations and expanding patient reach.
InhaleRx Limited has requested a trading halt on its securities pending an announcement related to a new drug development program and associated capital raising. This move is intended to manage the company’s continuous disclosure obligations and is expected to conclude with an announcement before the commencement of normal trading on 26 November 2025.
InhaleRx Limited has announced the issuance of 1,000,000 performance rights and 500,000 options as part of its employee incentive scheme. This strategic move is aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially strengthening its position in the competitive pharmaceutical market.
InhaleRx Limited has announced the issuance of performance rights and options to its Chief Scientific Officer, Dr. Rob Jenny, as part of an incentive plan aligned with key deliverables in their ongoing clinical trials for IRX-211 and IRX-616a. This strategic move is designed to align the CSO’s efforts with shareholder interests and ensure the successful progression of their clinical trials, which are crucial for the company’s growth and market positioning.